Author:
Thamer Mae,Zhang Yi,Kshirsagar Onkar,Cotter Dennis J.,Kaufman James S.
Reference23 articles.
1. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease;Pfeffer;N Engl J Med,2009
2. Lessons from TREAT: lower hemoglobin target, avoid ESA if possible;Singh;Nephrol Times,2009
3. Diabetes, anemia and CKD: why TREAT?;Singh;Curr Diabetes Rep,2010
4. FDA. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents in chronic kidney disease. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed April 12, 2013.
5. Critical and honest conversations: the evidence behind the “Choosing Wisely” campaign recommendations by the American Society of Nephrology;Williams;Clin J Am Soc Nephrol,2012
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献